HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Qi-Fu Li Selected Research

Nuclear Matrix-Associated Proteins

7/2014Regulatory role of nucleophosmin during the differentiation of human liver cancer cells.
7/2011The localization of hnRNP A2/B1 in nuclear matrix and the aberrant expression during the RA-induced differentiation of human neuroblastoma SK-N-SH cells.
1/2011Aberrant expression and localization of hnRNP-A2/B1 is a common event in human gastric adenocarcinoma.
5/2010Aberrant expression of nuclear matrix proteins during HMBA-induced differentiation of gastric cancer cells.
5/2010The aberrant expressions of nuclear matrix proteins during the apoptosis of human osteosarcoma cells.
11/2009Nuclear matrix protein, prohibitin, was down-regulated and translocated from nucleus to cytoplasm during the differentiation of osteosarcoma MG-63 cells induced by ginsenoside Rg1, cinnamic acid, and tanshinone IIA (RCT).
4/2009Differential expression of nuclear matrix proteins during the differentiation of human neuroblastoma SK-N-SH cells induced by retinoic acid.
2/2006Changes of nuclear matrix proteins following the differentiation of human osteosarcoma MG-63 cells.
8/2005Altered profiles of nuclear matrix proteins during the differentiation of human gastric mucous adenocarcinoma MGc80-3 cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Qi-Fu Li Research Topics

Disease

13Neoplasms (Cancer)
09/2021 - 08/2005
5Osteosarcoma (Osteogenic Sarcoma)
05/2010 - 02/2006
4Neuroblastoma
07/2011 - 04/2009
3Stomach Neoplasms (Stomach Cancer)
07/2014 - 05/2010
3Type 2 Diabetes Mellitus (MODY)
08/2013 - 04/2008
3Adenocarcinoma
01/2011 - 08/2005
2Carcinoma (Carcinomatosis)
08/2005 - 10/2000
1Skin Neoplasms (Skin Cancer)
09/2021
1Skin Diseases (Skin Disease)
09/2021
1Obesity
01/2018
1Hematologic Neoplasms (Hematological Malignancy)
12/2017
1Vasculitis (Vasculitides)
10/2016
1Blood Coagulation Disorders
10/2016
1Hyperthyroidism
10/2016
1Liver Neoplasms (Liver Cancer)
07/2014
1Metabolic Diseases (Metabolic Disease)
08/2012
1Non-alcoholic Fatty Liver Disease
08/2012
1Metabolic Syndrome (Dysmetabolic Syndrome X)
08/2012
1Goiter
01/2012
1Carcinogenesis
01/2011
1Bone Diseases (Bone Disease)
05/2010
1Brain Ischemia (Cerebral Ischemia)
01/2008
1Infarction (Infarctions)
01/2008
1Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
01/2008
1Genomic Instability
01/2008
1Hepatocellular Carcinoma (Hepatoma)
12/2002

Drug/Important Bio-Agent (IBA)

9Nuclear Matrix-Associated ProteinsIBA
07/2014 - 08/2005
7NucleophosminIBA
12/2017 - 01/2008
7hexamethylene bisacetamide (HMBA)IBA
07/2014 - 02/2006
6Proteins (Proteins, Gene)FDA Link
12/2017 - 08/2005
4hnRNP A2IBA
07/2011 - 07/2008
4ProhibitinsIBA
03/2011 - 07/2008
3Tretinoin (Retinoic Acid)FDA LinkGeneric
03/2011 - 04/2009
3Tachypleus tridentatus tachyplesin peptideIBA
03/2006 - 10/2000
2CurcuminIBA
09/2021 - 05/2010
2Pharmaceutical PreparationsIBA
10/2016 - 04/2008
2Messenger RNA (mRNA)IBA
07/2014 - 01/2008
2cinnamic acidIBA
11/2009 - 01/2008
2ginsenoside Rg1IBA
11/2009 - 01/2008
2tanshinoneIBA
11/2009 - 01/2008
1Food Additives (Food Additive)IBA
09/2021
1Reactive Oxygen Species (Oxygen Radicals)IBA
12/2017
1Anti-Bacterial Agents (Antibiotics)IBA
10/2016
1Imipenem Drug Combination Cilastatin (Primaxin)FDA Link
10/2016
1PropylthiouracilFDA Link
10/2016
1VildagliptinIBA
08/2013
1Metformin (Glucophage)FDA LinkGeneric
08/2013
1Alanine Transaminase (SGPT)IBA
08/2012
1LipidsIBA
08/2012
1Triglycerides (Triacylglycerol)IBA
08/2012
1Biomarkers (Surrogate Marker)IBA
01/2011
1Differentiation AntigensIBA
04/2009
1RibonucleoproteinsIBA
07/2008
1repaglinide (Prandin)FDA Link
04/2008
1Nateglinide (Starlix)FDA LinkGeneric
04/2008
1Hypoglycemic Agents (Hypoglycemics)IBA
04/2008
1Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
01/2008
1ChloridesIBA
01/2008
1PhosphoproteinsIBA
01/2008
1salicylhydroxamic acid (SHAM)IBA
01/2008
1Protective AgentsIBA
01/2008
13-n-butylphthalide (butylphthalide)IBA
01/2008
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2008
1Butyric Acid (Butanoic Acid)IBA
03/2006
1AcidsIBA
10/2000

Therapy/Procedure

4Therapeutics
08/2013 - 08/2005
2Glycemic Control
08/2013 - 06/2013
1Gastrectomy
01/2018
1Injections
06/2013
1Thyroidectomy
01/2012
1Drug Therapy (Chemotherapy)
01/2012
1Lasers (Laser)
08/2008